Immunotherapy Modeling in Organoids Co-preserving Tumor and Infiltrating Immune Compartments
共保存肿瘤和浸润免疫区室的类器官的免疫治疗模型
基本信息
- 批准号:10212018
- 负责人:
- 金额:$ 65.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-03-17 至 2026-02-28
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAcuteAddressAdoptive Cell TransfersAdoptive TransferAftercareAirAntigensAutologousB-LymphocytesBiopsyBioreactorsCellsCellular immunotherapyClinicalCoculture TechniquesComplexCutaneousDataDetectionDevelopmentEpithelialEquilibriumExhibitsHumanImmuneImmune EvasionImmune checkpoint inhibitorImmune responseImmune systemImmunologic SurveillanceImmunological ModelsImmunotherapeutic agentImmunotherapyIn VitroInterleukin-2InvadedLigandsLiquid substanceMHC antigenMalignant NeoplasmsMethodsModelingMusNatural Killer CellsNatureNodalOrganoidsOutcomePatientsPeptidesPhosphoric Monoester HydrolasesPopulationPrimary NeoplasmProgressive DiseaseProtein DephosphorylationReceptor InhibitionResistanceResolutionSamplingSystemT-Cell ReceptorT-LymphocyteT-Lymphocyte SubsetsT-cell receptor repertoireTNFRSF5 geneTechniquesTestingTherapeuticTherapeutic antibodiesTimeTransgenic MiceTumor AntigensTumor Cell LineTumor-DerivedTumor-Infiltrating LymphocytesTumor-infiltrating immune cellsair treatmentanti-PD-1anti-PD-1/PD-L1anti-PD-L1anti-PD1 therapyanti-tumor immune responsebasecancer immunotherapycell killingcheckpoint inhibitionclinical decision-makingclinical efficacycohesioncohortcytotoxicityexhaustfollow-uphuman modelimmune checkpoint blockadeimprovedin vitro Modelin vitro activityin vivomacrophagemelanomamouse modelneoplastic cellnetwork modelsnext generationnovelpatient responsepatient subsetsperipheral bloodpredictive markerpreservationprogrammed cell death ligand 1programmed cell death protein 1prospectivereceptorreconstitutionrecruitresponserestraintsingle-cell RNA sequencingskin squamous cell carcinomasuccesstreatment trialtrial comparingtumortumor immunologytumor progressiontumor specificitytumorigenesis
项目摘要
PROJECT SUMMARY
The immune system remarkably distinguishes between self and non-self/self-aberrant antigens, affording
exquisite anti-tumor specificity and inhibition of tumorigenesis. However, tumor immunosurveillance is
unfortunately opposed by tumor cell evasion of the immune response. Immune checkpoint blockade (ICB)
targeting PD-1, PD-L1, CD40 and others, as well as adoptive cell transfer (CAR-T, bulk TILs) favorably modulate
this equilibrium for therapeutic benefit. However, response rates are often incomplete, progressive disease is
common, and predictive biomarkers are suboptimal.
The development of next-generation immunotherapies has been hindered by a lack of in vitro models
that functionally recapitulate syngeneic interactions between tumor and infiltrating immune cells. In response,
we have developed organoid methods that culture primary human tumor biopsies together with their infiltrating
immune components as a cohesive unit without reconstitution. These “patient-derived tumor organoids” (PDO)
preserve tumor cells alongside endogenous T, B, NK cells and macrophages, robustly recapitulate the T cell
receptor clonotype repertoire of the original tumor, and crucially, manifest tumor-infiltrating lymphocyte (TIL)
expansion, activation and tumor cell killing in response to anti-PD-1/PD-L1 therapeutic antibodies (Cell, 2018).
The PDO system thus represents a holistic organoid model of human tumor-immune interactions.
Here, we leverage the PDO technique to investigate immunotherapeutic mechanisms and
treatments in PD-1-responsive cutaneous squamous cell carcinoma (cSCC) and melanoma, exploiting
pre- and post-treatment human biopsies and mouse models. Aim 1 hypothesizes that checkpoint inhibition
induces a complex and sequential network response involving immune-tumor and immune-immune crosstalk.
Thus, Aim 1 employs the ability to perform serial time-course sampling of PDOs to define a single cell RNA-seq
network cellular crosstalk model of the early anti-PD-1-stimulated anti-tumor immune response over multiple
acute time points typically inaccessible to clinical biopsies performed after months. Importantly, comparison of
this immune propagation in responding versus non-responding mouse and human organoids will define nodal
points conferring resistance. Aim 2 improves bulk TIL adoptive transfer immunotherapy by using PDOs as living
bioreactors to enrich tumor-reactive mouse and human melanoma TILs by anti-PD-1 checkpoint inhibition,
followed by testing of enhanced anti-tumor activity in vitro and in vivo. Lastly, Aim 3 performs a co-treatment
trial comparing anti-PD-1 responses of pre-treatment biopsy cSCC PDOs to clinical outcomes. Further, post-
treatment biopsy PDOs are re-challenged with anti-PD-1 and a novel agent inactivating PD-1 by
dephosphorylation. We thus utilize the holistic PDO model preserving endogenous tumor epithelial and immune
components en bloc to investigate and improve cancer immunotherapy via our team of Calvin Kuo (organoids),
Mark Davis and Chris Garcia (tumor immunology) and Anne Chang and Dimitri Colevas (cSCC clinicians).
项目概要
免疫系统可以显着区分自身抗原和非自身/自身异常抗原,从而提供
精湛的抗肿瘤特异性和抑制肿瘤发生。然而,肿瘤免疫监视
不幸的是,肿瘤细胞逃避了免疫反应。免疫检查点阻断 (ICB)
针对 PD-1、PD-L1、CD40 等以及过继细胞转移(CAR-T、批量 TIL)进行有利调节
这种治疗益处的平衡。然而,缓解率往往不完全,疾病进展是
常见的生物标志物和预测性生物标志物均不理想。
缺乏体外模型阻碍了下一代免疫疗法的发展
在功能上概括了肿瘤和浸润免疫细胞之间的同基因相互作用。作为回应,
我们开发了类器官方法,可培养原发性人类肿瘤活检及其浸润
免疫成分作为一个有凝聚力的单位而无需重组。这些“患者来源的肿瘤类器官”(PDO)
将肿瘤细胞与内源性 T、B、NK 细胞和巨噬细胞一起保存,有力地再现 T 细胞
原发肿瘤的受体克隆型库,最重要的是,表现出肿瘤浸润淋巴细胞(TIL)
对抗 PD-1/PD-L1 治疗性抗体的反应导致肿瘤细胞的扩增、激活和杀伤(Cell,2018)。
因此,PDO 系统代表了人类肿瘤-免疫相互作用的整体类器官模型。
在这里,我们利用 PDO 技术来研究免疫治疗机制并
PD-1 反应性皮肤鳞状细胞癌 (cSCC) 和黑色素瘤的治疗,利用
治疗前和治疗后的人体活检和小鼠模型。目标 1 假设检查点抑制
诱导涉及免疫-肿瘤和免疫-免疫串扰的复杂且连续的网络反应。
因此,目标 1 利用对 PDO 进行连续时间过程采样的能力来定义单细胞 RNA-seq
早期抗PD-1刺激的抗肿瘤免疫反应的网络细胞串扰模型
几个月后进行的临床活检通常无法获得急性时间点。重要的是,比较
这种在有反应与无反应的小鼠和人类类器官中的免疫传播将定义节点
赋予阻力的点。目标 2 通过使用 PDO 作为活体来改善批量 TIL 过继转移免疫疗法
通过抗 PD-1 检查点抑制来丰富肿瘤反应性小鼠和人类黑色素瘤 TIL 的生物反应器,
随后测试增强的体外和体内抗肿瘤活性。最后,Aim 3 进行协同处理
比较治疗前活检 cSCC PDO 的抗 PD-1 反应与临床结果的试验。此外,后
治疗活检 PDO 再次受到抗 PD-1 和一种新型灭活 PD-1 药物的攻击
去磷酸化。因此,我们利用整体 PDO 模型保留内源性肿瘤上皮和免疫
通过我们的 Calvin Kuo(类器官)团队研究和改进癌症免疫疗法,
Mark Davis 和 Chris Garcia(肿瘤免疫学)以及 Anne Chang 和 Dimitri Colevas(cSCC 临床医生)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CALVIN J KUO其他文献
CALVIN J KUO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CALVIN J KUO', 18)}}的其他基金
Intestinal organoid modeling of SARS-CoV-2-stimulated innate and adaptive immunity
SARS-CoV-2 刺激的先天性和适应性免疫的肠道类器官模型
- 批准号:
10319858 - 财政年份:2021
- 资助金额:
$ 65.79万 - 项目类别:
Core 2: Stanford Breast Metastasis Center Organoid Core
核心 2:斯坦福乳腺转移中心类器官核心
- 批准号:
10272393 - 财政年份:2021
- 资助金额:
$ 65.79万 - 项目类别:
Core 2: Stanford Breast Metastasis Center Organoid Core
核心 2:斯坦福乳腺转移中心类器官核心
- 批准号:
10704695 - 财政年份:2021
- 资助金额:
$ 65.79万 - 项目类别:
Intestinal organoid modeling of SARS-CoV-2-stimulated innate and adaptive immunity
SARS-CoV-2 刺激的先天性和适应性免疫的肠道类器官模型
- 批准号:
10654752 - 财政年份:2021
- 资助金额:
$ 65.79万 - 项目类别:
Immunotherapy Modeling in Organoids Co-preserving Tumor and Infiltrating Immune Compartments
共保存肿瘤和浸润免疫区室的类器官的免疫治疗模型
- 批准号:
10374163 - 财政年份:2021
- 资助金额:
$ 65.79万 - 项目类别:
Immunotherapy Modeling in Organoids Co-preserving Tumor and Infiltrating Immune Compartments
共保存肿瘤和浸润免疫区室的类器官的免疫治疗模型
- 批准号:
10586140 - 财政年份:2021
- 资助金额:
$ 65.79万 - 项目类别:
Intestinal organoid modeling of SARS-CoV-2-stimulated innate and adaptive immunity
SARS-CoV-2 刺激的先天性和适应性免疫的肠道类器官模型
- 批准号:
10450851 - 财政年份:2021
- 资助金额:
$ 65.79万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 65.79万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 65.79万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 65.79万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 65.79万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 65.79万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 65.79万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 65.79万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 65.79万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 65.79万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 65.79万 - 项目类别:
Operating Grants














{{item.name}}会员




